Focused On-demand Library for Intraflagellar transport protein 81 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8WYA0

UPID:

IFT81_HUMAN

Alternative names:

Carnitine deficiency-associated protein expressed in ventricle 1

Alternative UPACC:

Q8WYA0; Q2YDY1; Q8NB51; Q9BSV2; Q9UNY8

Background:

Intraflagellar transport protein 81 homolog (IFT81) is a crucial component of the intraflagellar transport complex B, playing a pivotal role in ciliogenesis and the regulation of SHH signaling. It forms a tubulin-binding module with IFT74, essential for the transport of tubulin within the cilium. IFT81's involvement in spermatogenesis, through the modulation of sperm flagella assembly and elongation, highlights its significance in cellular and developmental processes.

Therapeutic significance:

IFT81's association with Short-rib thoracic dysplasia 19, a condition marked by skeletal abnormalities and potential polydactyly, underscores its therapeutic potential. Understanding the role of IFT81 could open doors to potential therapeutic strategies for treating ciliopathies and improving outcomes for affected individuals.